PRAX - Praxis Precision Medicines, Inc.
IEX Last Trade
76.025
0.145 0.191%
Share volume: 3,019
Last Updated: Fri 27 Dec 2024 08:30:24 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$75.88
0.15
0.19%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
0.84%
1 Month
-1.55%
3 Months
35.26%
6 Months
96.73%
1 Year
240.53%
2 Year
128.71%
Key data
Stock price
$76.02
DAY RANGE
$75.09 - $78.25
52 WEEK RANGE
$22.65 - $86.93
52 WEEK CHANGE
$251.08
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
Company detail
CEO: Marcio Souza
Region: US
Website: praxismedicines.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: praxismedicines.com
Employees: 110
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression.
Recent news